[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@PTarantinoMD](/creator/twitter/PTarantinoMD)
"No time to wrap our head around two practice-changing trials (DB-09 PATINA) that a third innovation joins the frontline setting for HER2+ mBC. HER2CLIMB-05 is positive: tucatinib added to HP maintenance improves PFS. Could it prevent/delay brain mets 🧠"  
[X Link](https://x.com/PTarantinoMD/status/1978058367361761431) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-14T11:20Z 29.4K followers, 14.2K engagements


"Asian phase X trial of Sac-TMT (Trop2 ADC) vs chemo in pretreated HR+/HER2- MBC. Impressive doubling in PFS (8.3 vs XXX mo) positive OS trend. Compares favorably with data with SG despite similar ADC structure. Phase X testing ongoing in western pts. #ESMO25 #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979475599203942428) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T09:12Z 29.4K followers, 4711 engagements


"Impressive results from DB-11 with improvement in pCR rate (67% vs 56%) positive EFS trend & more favorable safety with T-DXd-THP vs ddAC-THP in high risk HER2+ eBC. Benefit mostly seen in N+ patients (90% of the pts). New neoadjuvant treatment option #ESMO25 #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979558764870328586) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T14:42Z 29.4K followers, 4272 engagements


"The KM curve of 2025 outside of breast oncology. Neoadjuvant EV+pembro more than halved the risk of recurrence and significantly improved OS among platinum-ineligible pts with bladder cancer. The tremendous power of ADCs + IO transforming oncology. #ESMO25 #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979571943268635040) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T15:35Z 29.4K followers, 5607 engagements


"Wow. All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs 30%. No benefit with low TILs. Unbelievable that we didnt get to see the TILs data from KN522 yet. Hope well see them soon. Congrats @vitti10 #ESMO25 #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979828482499915992) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-19T08:34Z 29.4K followers, 10.9K engagements


"Such a great day. Two Trop2 ADCs (SG Dato-DXd) just replaced 1L chemo for IO-ineligible mTNBC a huge unmet need. Pros and cons for the choice of each. Dato-DXd though looked safer with no G5 toxicity (vs X deaths with SG). Proactive management of ADC toxicities is key"  
[X Link](https://x.com/PTarantinoMD/status/1979837169582973355) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-19T09:08Z 29.4K followers, 6616 engagements


"Here you go ⚡"  
[X Link](https://x.com/PTarantinoMD/status/1969184815388807264) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-09-19T23:40Z 29.4K followers, 17K engagements


"Long term outcomes from POSITIVE (71 mo follow up) We could demonstrate that with long follow up interrupting ET to achieve pregnancy and resuming ET does not lead to increased risk of recurrence from breast cancer @fedrophd Total of XXX births 👏 #ESMO25 #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979167523758031346) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-17T12:48Z 29.4K followers, 5296 engagements


"Trastuzumab botidotin (MMAF stable ADC) vs T-DM1 for HER2+ BC. Major PFS benefit (11.1 vs XXX mo) at the expense of XX% ocular toxicities. The good: a highly-active NON-TOPO1 ADC. The bad: ocular toxicities impact QoL. Stable ADC well tolerated ADC. #ESMO25 #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979479019394617559) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T09:25Z 29.4K followers, 3864 engagements


"One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases anticipating the expansion of T-DXd to the curative setting two Trop2 ADCs reaching first-line mTNBC X novel ET-based combos adjuvant CDK4/6i improving OS. See you in Berlin #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1976244542853808316) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-09T11:13Z 29.4K followers, 32.6K engagements


"1 mg/kg of pembro saturates PD1. Could we give a lower dose and reduce financial tox In the PLANeT randomized ph X trial low dose pembro (50 mg for X Q6W doses) added to neoadjuvant ddAC-T significantly improved pCR for stage II-III TNBC (delta 13%). #ESMO25 #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979164310715670617) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-17T12:35Z 29.4K followers, 13.8K engagements


"How do adjuvant CDK4/6i impact the biology of breast cancer that recurs Angie DeMichele highlights our RW study led by @CCortiMD which found XX% of pts losing ER expression and having short 1L PFS if relapsing after abema. Published in @ESMO_Open #ESMO25 #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979177751958487495) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-17T13:28Z 29.4K followers, 12.2K engagements


"The KM curve of 2025: among high risk patients with HER2+ eBC and RD adjuvant T-DXd halved the risk of recurrence vs T-DM1. New SoC for pts with: -inoperable disease at diagnosis -node-positive RD XXXX% rate of ILD X deaths. Remember to monitor the lungs #ESMOAmbassadors"  
[X Link](https://x.com/PTarantinoMD/status/1979565393258979341) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T15:09Z 29.4K followers, 5186 engagements


"#ESMO25 will bring two new combos for the treatment of HR+/HER2- breast cancer. How would you treat a patient with HR+/HER2- MBC with visceral mets who progresses after XX months on 1L letrozole/ribociclib and is found to have an ESR1 mutation (assuming all available)"  
[X Link](https://x.com/PTarantinoMD/status/1980147762818859162) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-20T05:43Z 29.4K followers, 8896 engagements


"A lot of heterogeneity in the management of stage II HER2+ breast cancer. The only consensus - no anthracyclines"  
[X Link](https://x.com/PTarantinoMD/status/1980520582140879066) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-21T06:24Z 29.4K followers, 2647 engagements